Xwell, Inc. (XWEL) Stock Price & Analysis
Xwell, Inc. (XWEL) rose 0.00% to USD 1.05 as of July 26, 2026 at 00:04 UTC, according to Nexqual real-time market data.
XWEL last closed at USD 1.05; the session ranged USD 1.05–1.09 on volume of 26,251 shares. Market capitalization is $8.87M, with a 52-week range of USD 0.26–2.2 (NCM). Source: Nexqual, July 26, 2026 at 00:04 UTC.
Key Statistics (as of July 26, 2026 at 00:04 UTC)
| Price | USD 1.05 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.05 |
| Open | USD 1.09 |
| Day Range | USD 1.05 – 1.09 |
| 52-Week Range | USD 0.26 – 2.2 |
| Volume | 26,251 shares |
| Market Cap | $8.87M |
| Exchange | NCM |
Technical Analysis (XWEL)
Nexqual's technical model rates XWEL "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 00:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.57 (neutral) |
| vs SMA50 | Below (USD 1.18) |
| MACD | -0.03 (negative) |
Analyst Ratings (XWEL)
Wall Street analysts rate XWEL "None", per Nexqual as of July 26, 2026 at 00:04 UTC.
| Consensus Rating | None |
|---|
Earnings (XWEL)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -0.77 vs est -0.8 ▲ beat |
| 2023-06-30 | USD -1.37 vs est -1.4 ▲ beat |
| 2023-03-31 | USD -1.3 vs est -2.6 ▲ beat |
| 2022-12-31 | USD -1.75 vs est -1.6 ▼ miss |
Source: Nexqual, July 26, 2026 at 00:04 UTC.
Financials & Fundamentals (XWEL)
| Total Revenue | $28.82M |
|---|---|
| Revenue Growth (YoY) | -5.50% |
| Gross Margin | +29.63% |
| Operating Margin | -81.56% |
| Profit Margin | -81.44% |
| ROE | -333.68% |
| Debt / Equity | 82.5 |
| Current Ratio | 2.35 |
| Total Cash | $16.81M |
| Total Debt | $8.31M |
| Free Cash Flow | $-5.81M |
Source: Nexqual, July 26, 2026 at 00:04 UTC.
Financial Health Score (XWEL)
Nexqual rates Xwell, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 00:04 UTC.
| Growth | Critical — Revenue -24% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Gross margin 30%, operating -82% |
| Balance Sheet | Mixed — $17M cash vs $8M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -334%, ROA -29.1% |
Ownership (XWEL)
| Insider Ownership | +18.48% |
|---|---|
| Institutional Ownership | +14.76% |
| Shares Outstanding | 8.44M |
| Float | 6.37M |
| Short % of Float | +3.87% |
Source: Nexqual, July 26, 2026 at 00:04 UTC.
Leadership (XWEL)
Xwell, Inc. is led by Ezra T. Ernst (age 56), President, CEO & Director, per Nexqual as of July 26, 2026 at 00:04 UTC.
| President, CEO & Director | Ezra T. Ernst (age 56) |
|---|---|
| Chief Financial Officer | Thomas Ian Brown (age 55) |
| Chief Operating Officer | Patti Ward |
| Marketing Director | Mike Heronime |
Major Backers & Investors (XWEL)
Notable institutional backers of Xwell, Inc. include Jane Street Group, LLC, Fidelity, Morgan Stanley, according to Nexqual as of July 26, 2026 at 00:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 0.97% |
| Fidelity | 0.54% |
| Morgan Stanley | 0.26% |
| UBS Group AG | 0.14% |
| Integrated Wealth Concepts LLC | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.5% |
| BlackRock | 0.97% |
| Geode Capital | 0.8% |
| State Street | 0.19% |
Source: Nexqual, July 26, 2026 at 00:04 UTC.
From Xwell, Inc.'s Latest SEC 10-K Filing (filed 2026-04-01)
Key Strengths & Strategy (as disclosed to the SEC)
- XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally.
- It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center.
- The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products.
- The XpresTest segment offers COVID-19 and other medical testing to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. customs and border protection agents; aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program; and various services and support, including technical support services and advanced services.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MGRX | Mangoceuticals, Inc. | USD 0.52 | ▲ 1.9% |
| QNCX | Quince Therapeutics, Inc. | USD 17.86 | ▼ 3.69% |
| SNAL | Snail, Inc. | USD 5.14 | ▲ 5.54% |
| SXTP | 60 Degrees Pharmaceuticals, Inc | USD 1.48 | ▼ 4.52% |
| CISS | C3is Inc. | USD 0.52 | ▼ 68.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 00:04 UTC. This page is informational and not investment advice.